The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease

Treatment options for patients with Epstein-Barr Virus-driven lymphoproliferative diseases (EBV-LPD) are limited. Chemo-immunotherapeutic approaches often lead to immune suppression, risk of lethal infection and EBV reactivation, thus it is essential to identify agents that can deliver direct anti-t...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Patton, John T., Lustberg, Mark E., Lozanski, Gerard, Garman, Sabrina L., Towns, William H., Drohan, Callie M., Lehman, Amy, Zhang, Xiaoli, Bolon, Brad, Pan, Li, Kinghorn, A. Douglas, Grever, Michael R., Lucas, David M., Baiocchi, Robert A.
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2014
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4413611/
https://ncbi.nlm.nih.gov/pubmed/25393910
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items